Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Recruiting
N/A
Interventional Study
Non-muscle Invasive Bladder Cancer (NMIBC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 56 (estimated)
- Sponsor
- Lahey Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* AUA high-risk bladder cancer1
* Received induction BCG or gemcitabine/docetaxel
* Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
Exclusion Criteria:
* High-risk NMIBC within 3 years
* Prior induction intravesical therapy
* Va…
Contacts